An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Adverse Events (AEs)

  Measured over: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

• Number of Participants With Serious Adverse Events (SAEs)

  Measured over: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

• Number of Participants With Adverse Events Leading to Discontinuation

  Measured over: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

• Number of Participants Who Died

  Measured over: From first dose of study medication until study closure (Up to approximately 144 months)

• Number of Participants With Laboratory Abnormalities in Specific Liver Tests

  Measured over: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

• Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

  Measured over: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

• Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2

  Measured over: From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

• Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6

  Measured over: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)

Changes Tremor has spotted